Navigation Links
Interim Analysis Supports Continuation of Cell Genesys' VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
Date:1/14/2008

America and Europe.

The company's second Phase 3 trial, VITAL-2, is a multi-center, randomized, controlled Phase 3 clinical trial designed to evaluate the safety and efficacy of GVAX immunotherapy for prostate cancer used in combination with Taxotere chemotherapy compared to the use of Taxotere chemotherapy and prednisone in HRPC patients with metastatic disease who are symptomatic with cancer-related pain. The primary endpoint of the trial is also an improvement in survival. VITAL-2 was initiated in June 2005 and is currently enrolling patients at approximately 90 sites in North America and Europe. The company expects to complete enrollment of approximately 600 patients in the first half of 2009 and if this is achieved, to have a sufficient number of events for a pre-planned interim analysis at that time.

The U.S. Food and Drug Administration (FDA) granted Cell Genesys Special Protocol Assessments (SPAs) for both VITAL-1 and VITAL-2. The SPA is a process that allows for official FDA evaluation of a Phase 3 clinical trial and provides trial sponsors with a binding written agreement that the design and analysis of the study are adequate to support a license application submission if that study is performed according to the SPA. Cell Genesys completed the modifications requested by FDA during the review process.

About GVAX Cancer Immunotherapies

GVAX cancer immunotherapies are non patient-specific investigational therapeutics comprised of whole tumor cells that have been modified to secrete GM-CSF (granulocyte-macrophage colony stimulating factor), an immune stimulatory hormone, and then irradiated for safety. GVAX is designed to be administered through intradermal injections on an outpatient basis. To date, over 600 patients have been treated with GVAX cancer immunotherapies in Phase 1 and Phase 2 clinical trials for multiple indications, including prostate cancer, pancreatic cancer, and leukemia. The company is currently manufacturing GV
'/>"/>

SOURCE Cell Genesys, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
3. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
4. Interim Safety Data Favorable for Vicals Phase 2 Trial of DNA Vaccine Against CMV
5. Interim Phase 2 Data for Exelixis XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
6. Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium
7. Grantees of the Avon Foundation Breast Cancer Prevention Research Initiative Gather in Houston to Report Interim Findings
8. Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program
9. Interim Safety Analysis Supports Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma
10. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
11. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , July 10, 2014  Valeant Pharmaceuticals International, Inc. ... announced it has completed the sale to Galderma of ... owned or held by Valeant for $1.4 billion in ... S.A, which recently completed its acquisition of Galderma. ... of our products to a company that is firmly ...
(Date:7/10/2014)... CVS Caremark Corporation (NYSE: CVS ) ... quarterly dividend of $0.275 (27.5 cents) per share on the ... 2014, to holders of record on July 21, 2014. ... dedicated to helping people on their path to better health ... United States . Through the company,s more than 7,600 ...
(Date:1/15/2014)... , Jan. 15, 2014 Most osteoporosis patients want ... a recent online survey* sponsored by Mission Pharmacal Company. ... National Osteoporosis Foundation online support community, revealed that 74 ... that comes in a form other than a pill ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3
(Date:7/11/2014)... When the mercury rises, heat can strain the limits ... takes on a heavier load in hot weather to keep ... the Harvard Men's Health Watch . , For otherwise ... knowing their limits and drinking enough fluids. But what about ... sensitive to the heat," says Dr. Joanne Foody, Director of ...
(Date:7/11/2014)... 11, 2014 Los Angeles dental ... he uses mini and full mouth implants to replace ... feature that distinguishes dental implants from other tooth replacements: ... the crowns. This alone prevents the long-term complications of ... advantages related to comfort, appearance and systemic health. Mini ...
(Date:7/11/2014)... A new study challenges the widely held belief that light ... Researchers analyzed more than 50 studies that examined drinking habits ... found that those with a form of a gene tied ... gene affects how a person,s body breaks down alcohol, resulting ... this variant has been shown to lead to lower drinking ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 Cancer researchers ... have a significant impact on how patients respond to ... for mesothelioma. Surviving Mesothelioma has the full story. ... , Researchers at the University of Ljubljana and the ... pemetrexed for different types of polymorphisms. They found ...
(Date:7/11/2014)... 11, 2014 Anterior Cruciate Ligament (ACL) ... the type of material used to create a new ... game, say researchers presenting their work today at the ... Medicine ( AOSSM ). , “Our study ... (tissue harvested from a donor) fail more frequently than ...
Breaking Medicine News(10 mins):Health News:Take Common Sense Steps to Stay Safe This Summer, from the July 2014 Harvard Men's Health Watch 2Health News:Take Common Sense Steps to Stay Safe This Summer, from the July 2014 Harvard Men's Health Watch 3Health News:Dental Implant Dentist, Kevin Sands DDS, Now Uses Mini and Full Mouth Implants to Replace Missing Teeth 2Health News:A Little Alcohol May Not Be Good for Your Heart After All 2Health News:New Research Finds Genetic Variables Impact Chemotherapy Response, According to Surviving Mesothelioma 2Health News:ACL Reconstructions May Last Longer With Autografts 2
... disorders in this country has nearly doubled in the past ... psychologists and therapists are charged with the task, but many ... date and lack scientific rigor. This is in part because ... programs and for-profit training centersare not grounded in science. ...
... today for excellence in research, advancing oral health ... receive the 2009 American Dental Association,s (ADA) Gold Medal Award ... presentation during a meeting of the ADA,s House of ... every three years, the award honors individuals who contribute to ...
... Beginning October 1st, The Peninsula Chicago will dedicate itself to ... several cancer research and education organizations. , "We all know ... some way and this is why we at The Peninsula ... manager of The Peninsula Chicago. "In addition to the initiatives ...
... the largest non-government, not-for-profit funding source of cancer research ... research and training grants totaling $45,097,000 to 61 institutions ... 2009. The grants go into effect beginning January 1, ... Cancer Society has funded research and training of health ...
... ... Medical Center,s Emergency Department will begin using a new procedure, called therapeutic hypothermia, to ... , ... 2009 -- On October 19, 2009, Baptist Medical Center,s Emergency Department will ...
... Organization Exclusively for LTC Consumers Receives ... (formerly the National Citizens, Coalition for Nursing Home Reform) announced ... will help strengthen the organization,s role as a voice for ... organization exclusively for residents and their families and is a ...
Cached Medicine News:Health News:Where's the science? The sorry state of psychotherapy 2Health News:ADA's 2009 Gold Medal Award Presentation Set for 150th Annual Session 2Health News:The Peninsula Chicago Gives Back During Breast Cancer Awareness Month 2Health News:American Cancer Society awards 94 new research and training grants at 61 institutions nationwide 2Health News:American Cancer Society awards 94 new research and training grants at 61 institutions nationwide 3Health News:American Cancer Society awards 94 new research and training grants at 61 institutions nationwide 4Health News:American Cancer Society awards 94 new research and training grants at 61 institutions nationwide 5Health News:Baptist Using Therapeutic Hypothermia to Save Heart Attack Patients 2Health News:Long-Term Care Consumer Voices Strengthened 2
... Addressing the key clinical and economic issues ... System is designed to maximize tension control ... The system combines efficient instrumentation with a ... Grip system is indicated for general orthopaedic ...
... In 1985, the worlds first ... by Howmedica Osteonics as a means ... wire for trochanteric reattachment procedures. Today, ... papers demonstrating clinical successes, the Dall-Miles™ ...
The Assistant Free Self-Retaining Hip Surgery Retractor System is used for hip arthroplasty and hip fracture surgery....
... have become the accepted standard for,excellence and ... AML Total Hip System was the first ... meet the needs for biological fixation in ... 15 years of documented clinical performance, the ...
Medicine Products: